Failure of thrombus to resolve in urokinase-type plasminogen activator gene-knockout mice: Rescue by normal bone marrow-derived cells

Circulation

Volumn 107, Issue 6, 2003, Pages 869-875

  Singh, I ^a,b   Burnand, K G ^a   Collins, M ^a   Luttun, A ^b   Collen, D ^b   Boelhouwer, B ^a   Smith, Alberto ^a,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Leukocytes; Plasminogen activators; Thrombus; Veins

Indexed keywords

BETA GALACTOSIDASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; COMPUTER ANALYSIS; CONTROLLED STUDY; FIBRINOLYSIS; IMAGE ANALYSIS; INFERIOR CAVA VEIN; KNOCKOUT MOUSE; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VEIN THROMBOSIS;

ANIMALS; BONE MARROW TRANSPLANTATION; CELL COUNT; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FIBRINOLYSIS; GENE TARGETING; GENES, REPORTER; MACROPHAGES; MICE; MICE, KNOCKOUT; MONOCYTES; REMISSION, SPONTANEOUS; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR; VASCULAR PATENCY; VENA CAVA, INFERIOR; VENOUS THROMBOSIS;

EID: 0037448801     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000050149.22928.39     Document Type: Article

References (34)

1. Browse N. Diseases of the Veins. Oxford, UK: Arnold; 1998.
2. Haas S. Deep vein thrombosis: beyond the operating table. Orthopedics. 2000;23(6 suppl):s629-s632.
3. Wells PS, Forster AJ. Thrombolysis in deep vein thrombosis: is there still an indication? Thromb Haemost. 2001;86:499-508.
4. Sevitt S. The mechanisms of canalisation in deep vein thrombosis. J Pathol. 1973;110:153-165.
5. Meissner MH, Manzo RA, Bergelin RO, et al. Deep venous insufficiency: the relationship between lysis and subsequent reflux. J Vasc Surg. 1993;18:596-605.
6. Tabrizi P, Wang L, Seeds N, et al. Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background. Arterioscler Thromb Vasc Biol. 1999;19:2801-2806.
7. Bugge TH, Flick MJ, Danton MJ, et al. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci U S A. 1996;93:5899-5904.
8. Ploplis VA, French EL, Carmeliet P, et al. Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice. Blood. 1998;91:2005-2009.
9. Cox JST. The maturation of canalisation of thrombi. Surg Gynaecol Obstet. 1963;116:153-165.
10. Leibovich SJ, Wiseman DM. Macrophages, wound repair and angiogenesis. Prog Clin Biol Res. 1988;266:131-145.
11. Lijnen HR. Elements of the fibrinolytic system. Ann N Y Acad Sci. 2001;936:226-236.
12. McGuinness CL, Humphries J, Waltham M, et al. Recruitment of labelled monocytes by experimental venous thrombi. Thromb Haemost. 2001;85:1018-1024.
13. Humphries J, McGuinness CL, Smith A, et al. Monocyte chemotactic protein-1 (MCP-1) accelerates the organization and resolution of venous thrombi. J Vasc Surg. 1999;30:894-899.
14. Northeast AD, Soo KS, Bobrow LG, et al. The tissue plasminogen activator and urokinase response in vivo during natural resolution of venous thrombus. J Vasc Surg. 1995;22:573-579.
15. Soo KS, Northeast AD, Happerfield LC, et al. Tissue plasminogen activator production by monocytes in venous thrombolysis. J Pathol. 1996;178:190-194.
16. Quarmby J, Smith A, Collins M, et al. A model of in vivo human venous thrombosis that confirms changes in the release of specific soluble cell adhesion molecules in experimental venous thrombogenesis. J Vasc Surg. 1999;30:139-147.
17. Singh I, Smith A, Vanzieleghem B, et al. Antithrombotic effects of controlled inhibition of factor VIII with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model. Blood. 2002;99:3235-3240.
18. Carmeliet P, Schoonjans L, Kieckens L, et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature. 1994;368:419-424.
19. Fazio S, Babaev VR, Murray AB, et al. Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages. Proc Natl Acad Sci U S A. 1997;94:4647-4652.
20. van Hinsbergh VW, Koolwijk P, Hanemaaijer R. Role of fibrin and plasminogen activators in repair-associated angiogenesis: in vitro studies with human endothelial cells. EXS. 1997;79:391-411.
21. Rohovsky S, D'Amore PA. Growth factors and angiogenesis in wound healing. In: Zeigler TR, Pierce GF, Herndon DN, ed. Growth Factors and Wound Healing. New York, NY: Springer: 1997.
22. Blasi F. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system. Thromb Haemost. 1999;82:298-304.
23. Cuzner ML, Opdenakker G. Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. J Neuroimmunol 1999;94:1-14.
24. Heymans S, Luttun A, Nuyens D, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med. 1999;5:1135-1142.
25. Simon DI, Ezratty AM, Francis SA, et al. Fibrin(ogen) is internalized and degraded by activated human monocytoid cells via Mac-1 (CD11b/CD18): a nonplasmin fibrinolytic pathway. Blood. 1993;82:2414-2422.
26. Moldovan NI, Goldschmidt-Clermont PJ, Parker-Thornburg J, et al. Contribution of monocytes/macrophages to compensatory neovascularization: the drilling of metalloelastase-positive tunnels in ischemic myocardium. Circ Res. 2000;87:378-384.
27. Burnand KG, Gaffney PJ, McGuinness CL, et al. The role of the monocyte in the generation and dissolution of arterial and venous thrombi. Cardiovasc Surg. 1998;6:119-125.
28. Issekutz TB, Issekutz AC, Movat HZ. The in vivo quantitation and kinetics of monocyte migration into acute inflammatory tissue. Am J Pathol. 1981;103:47-55.
29. Shi Q, Rafii S, Wu MH, et al. Evidence for circulating bone marrow-derived endothelial cells. Blood. 1998;92:362-367.
30. Rafii S, Heissig B, Hattori K. Efficient mobilization and recruitment of marrow-derived endothelial and hematopoietic stem cells by adenoviral vectors expressing angiogenic factors. Gene Ther. 2002;9:631-641.
31. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999;85:221-228.
32. Marchetti S, Gimond C, Iljin K, et al. Endothelial cells genetically selected from differentiating mouse embryonic stem cells incorporate at sites of neovascularization in vivo. J Cell Sci. 2002;115:2075-2085.
33. Hillebrands JL, Klatter FA, van Dijk WD, et al. Bone marrow does not contribute substantially to endothelial-cell replacement in transplant arteriosclerosis. Nat Med. 2002;8:194-195.
34. Schleef RR, Olman MA, Miles LA, et al. Modulating the fibrinolytic system of peripheral blood mononuclear cells with adenovirus. Hum Gene Ther. 2001;12:439-445.